Ad is loading...
BEAM
Price
$23.58
Change
-$0.00 (-0.00%)
Updated
Nov 21 closing price
102 days until earnings call
DNA
Price
$6.59
Change
-$0.00 (-0.00%)
Updated
Nov 21 closing price
Ad is loading...

BEAM vs DNA

Header iconBEAM vs DNA Comparison
Open Charts BEAM vs DNABanner chart's image
Beam Therapeutics
Price$23.58
Change-$0.00 (-0.00%)
Volume$1.01M
CapitalizationN/A
Ginkgo Bioworks Holdings
Price$6.59
Change-$0.00 (-0.00%)
Volume$787.71K
CapitalizationN/A
BEAM vs DNA Comparison Chart
Loading...
BEAM
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
DNA
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
View a ticker or compare two or three
VS
BEAM vs. DNA commentary
Nov 23, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BEAM is a StrongBuy and DNA is a Hold.

COMPARISON
Comparison
Nov 23, 2024
Stock price -- (BEAM: $23.58 vs. DNA: $6.59)
Brand notoriety: BEAM and DNA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BEAM: 94% vs. DNA: 64%
Market capitalization -- BEAM: $2.07B vs. DNA: $378.79M
BEAM [@Biotechnology] is valued at $2.07B. DNA’s [@Biotechnology] market capitalization is $378.79M. The market cap for tickers in the [@Biotechnology] industry ranges from $450.11B to $0. The average market capitalization across the [@Biotechnology] industry is $2.63B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BEAM’s FA Score shows that 0 FA rating(s) are green whileDNA’s FA Score has 1 green FA rating(s).

  • BEAM’s FA Score: 0 green, 5 red.
  • DNA’s FA Score: 1 green, 4 red.
According to our system of comparison, BEAM is a better buy in the long-term than DNA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BEAM’s TA Score shows that 3 TA indicator(s) are bullish while DNA’s TA Score has 5 bullish TA indicator(s).

  • BEAM’s TA Score: 3 bullish, 6 bearish.
  • DNA’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, DNA is a better buy in the short-term than BEAM.

Price Growth

BEAM (@Biotechnology) experienced а -10.38% price change this week, while DNA (@Biotechnology) price change was -9.85% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.14%. For the same industry, the average monthly price growth was -4.97%, and the average quarterly price growth was +4.04%.

Reported Earning Dates

BEAM is expected to report earnings on Mar 04, 2025.

DNA is expected to report earnings on Nov 11, 2024.

Industries' Descriptions

@Biotechnology (+2.14% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
BEAM($2.07B) has a higher market cap than DNA($413M). BEAM YTD gains are higher at: -13.373 vs. DNA (-90.251). BEAM has higher annual earnings (EBITDA): -160.83M vs. DNA (-630.64M). BEAM has more cash in the bank: 926M vs. DNA (616M). BEAM has less debt than DNA: BEAM (162M) vs DNA (446M). BEAM has higher revenues than DNA: BEAM (350M) vs DNA (217M).
BEAMDNABEAM / DNA
Capitalization2.07B413M502%
EBITDA-160.83M-630.64M26%
Gain YTD-13.373-90.25115%
P/E RatioN/AN/A-
Revenue350M217M161%
Total Cash926M616M150%
Total Debt162M446M36%
TECHNICAL ANALYSIS
Technical Analysis
BEAMDNA
RSI
ODDS (%)
Bearish Trend 2 days ago
89%
Bullish Trend 2 days ago
86%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
86%
Bullish Trend 2 days ago
74%
Momentum
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
83%
MACD
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
88%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
85%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
83%
Bearish Trend 2 days ago
87%
Advances
ODDS (%)
Bullish Trend 4 days ago
81%
Bullish Trend 12 days ago
78%
Declines
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 5 days ago
86%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
83%
Bullish Trend 2 days ago
69%
Aroon
ODDS (%)
N/A
Bullish Trend 2 days ago
90%
View a ticker or compare two or three
Ad is loading...
BEAM
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
DNA
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FTHCX93.261.17
+1.27%
Fidelity Advisor Technology C
IVRTX29.870.20
+0.67%
VY® CBRE Real Estate S2
ASRIX8.270.02
+0.24%
Invesco Global Real Estate Income R5
GAIGX22.36N/A
N/A
Gabelli International Growth A
GUXPX6.10N/A
N/A
Gabelli Utilities C

DNA and

Correlation & Price change

A.I.dvisor indicates that over the last year, DNA has been loosely correlated with VCYT. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if DNA jumps, then VCYT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DNA
1D Price
Change %
DNA100%
+3.62%
VCYT - DNA
58%
Loosely correlated
-0.66%
NTLA - DNA
56%
Loosely correlated
+5.18%
ABCL - DNA
53%
Loosely correlated
+1.87%
PRME - DNA
49%
Loosely correlated
-0.67%
BEAM - DNA
47%
Loosely correlated
-3.72%
More